These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 35165171)

  • 21. Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment.
    Belujon P; Lodge DJ; Grace AA
    Mov Disord; 2010 Aug; 25(11):1568-76. PubMed ID: 20623773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N; Martín AB; Mendialdua A; Moratalla R
    Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease.
    González-Aparicio R; Moratalla R
    Neurobiol Dis; 2014 Feb; 62():416-25. PubMed ID: 24140894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. D2R signaling in striatal spiny neurons modulates L-DOPA induced dyskinesia.
    Florio E; Serra M; Lewis RG; Kramár E; Freidberg M; Wood M; Morelli M; Borrelli E
    iScience; 2022 Oct; 25(10):105263. PubMed ID: 36274959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of glutamic acid decarboxylase (Gad67) in striatal neurons expressing the Drdr1a dopamine receptor prevents L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
    Zhang K; Chammas C; Soghomonian JJ
    Neuroscience; 2015 Sep; 303():586-94. PubMed ID: 26188284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical and genetic heterogeneity of paroxysmal dyskinesias.
    Gardiner AR; Jaffer F; Dale RC; Labrum R; Erro R; Meyer E; Xiromerisiou G; Stamelou M; Walker M; Kullmann D; Warner T; Jarman P; Hanna M; Kurian MA; Bhatia KP; Houlden H
    Brain; 2015 Dec; 138(Pt 12):3567-80. PubMed ID: 26598494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
    J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The basal ganglia and cerebellum interact in the expression of dystonic movement.
    Neychev VK; Fan X; Mitev VI; Hess EJ; Jinnah HA
    Brain; 2008 Sep; 131(Pt 9):2499-509. PubMed ID: 18669484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Keber U; Klietz M; Carlsson T; Oertel WH; Weihe E; Schäfer MK; Höglinger GU; Depboylu C
    Neuroscience; 2015 Jul; 298():302-17. PubMed ID: 25892702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Pathogenesis of Paroxysmal Kinesigenic Dyskinesia: Current Concepts.
    Li ZY; Tian WT; Huang XJ; Cao L
    Mov Disord; 2023 Apr; 38(4):537-544. PubMed ID: 36718795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case of familial paroxysmal nonkinesigenic dyskinesia due to mutation of the PNKD gene in Chinese Mainland.
    Liang S; Yu X; Zhang S; Tai J
    Brain Res; 2015 Jan; 1595():120-6. PubMed ID: 25107857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Genetic Mouse Model of Parkinson's Disease Shows Involuntary Movements and Increased Postsynaptic Sensitivity to Apomorphine.
    Brehm N; Bez F; Carlsson T; Kern B; Gispert S; Auburger G; Cenci MA
    Mol Neurobiol; 2015 Dec; 52(3):1152-1164. PubMed ID: 25307288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zooming in on the small: the plasticity of striatal dendritic spines in L-DOPA-induced dyskinesia.
    Fieblinger T; Cenci MA
    Mov Disord; 2015 Apr; 30(4):484-93. PubMed ID: 25759263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia.
    Cerovic M; Bagetta V; Pendolino V; Ghiglieri V; Fasano S; Morella I; Hardingham N; Heuer A; Papale A; Marchisella F; Giampà C; Calabresi P; Picconi B; Brambilla R
    Biol Psychiatry; 2015 Jan; 77(2):106-15. PubMed ID: 24844602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inversion of dopamine responses in striatal medium spiny neurons and involuntary movements.
    Liang L; DeLong MR; Papa SM
    J Neurosci; 2008 Jul; 28(30):7537-47. PubMed ID: 18650331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian rats.
    Cantuti-Castelvetri I; Hernandez LF; Keller-McGandy CE; Kett LR; Landy A; Hollingsworth ZR; Saka E; Crittenden JR; Nillni EA; Young AB; Standaert DG; Graybiel AM
    PLoS One; 2010 Nov; 5(11):e13861. PubMed ID: 21085660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
    Azkona G; Sagarduy A; Aristieta A; Vazquez N; Zubillaga V; Ruíz-Ortega JA; Pérez-Navarro E; Ugedo L; Sánchez-Pernaute R
    Neuropharmacology; 2014 Apr; 79():726-37. PubMed ID: 24333147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Striatal synaptic plasticity: implications for motor learning and Parkinson's disease.
    Pisani A; Centonze D; Bernardi G; Calabresi P
    Mov Disord; 2005 Apr; 20(4):395-402. PubMed ID: 15719415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapamycin, by Inhibiting mTORC1 Signaling, Prevents the Loss of Striatal Bidirectional Synaptic Plasticity in a Rat Model of L-DOPA-Induced Dyskinesia.
    Calabrese V; Di Maio A; Marino G; Cardinale A; Natale G; De Rosa A; Campanelli F; Mancini M; Napolitano F; Avallone L; Calabresi P; Usiello A; Ghiglieri V; Picconi B
    Front Aging Neurosci; 2020; 12():230. PubMed ID: 32848709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.